Turn Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $281.8M
- Price
- $9.46
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.84%
- Volume
- 22.2K
About
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
Quick stats
Shares outstanding29.8M
Computed float13.4M
Float / shares44.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002023016
AI Summary
AI-generated1/20
standardbullishclinical trial
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
Turn Therapeutics published peer-reviewed research in the journal Life demonstrating that its lead candidate GX-03 selectively reduced key inflammatory drivers in a murine dermatitis model.
Pretreatment with GX-03 reduced IL-36 by approximately 50% and IL-31 by nearly 68%, resulting in a 66% reduction in clinical dermatitis severity compared to controls.
The findings support the company's strategy of modifying the local skin environment upstream to prevent inflammation; GX-03 is currently being evaluated in a randomized, double-blind, vehicle-controlled clinical trial for atopic dermatitis.